Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.880
Filtrar
1.
BMC Pulm Med ; 24(1): 434, 2024 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-39223526

RESUMEN

BACKGROUND: Phlegm is prevalent symptom in patients with chronic obstructive pulmonary disease (COPD). Few studies have investigated the effectiveness of N-acetylcysteine (NAC) nebulizer therapy in COPD patients. We evaluated the effect of nebulized NAC on the improvement of phlegm symptom in COPD patients. METHODS: This was a 12-week, prospective, single-arm, open-label, phase IV multi-center trial (NCT05102305, Registration Date: 20-October-2021). We enrolled patients aged ≥ 40 years with post bronchodilator forced expiratory volume in one second/forced vital capacity (FEV1/FVC) < 0.7 and COPD assessment test (CAT) phlegm score ≥ 2; the patients were current or ex-smoker with smoking pack-years ≥ 10. The primary endpoint was to determine the change in CAT phlegm score at 12 weeks compared to the baseline. Patients were assessed at baseline, 4, 8, and 12 weeks of treatment using the CAT score. RESULTS: In total, 100 COPD patients were enrolled from 10 hospitals. The mean age of the patients was 71.42 ± 8.20 years, with 19.78% being current-smokers and 80.22% being ex-smokers. The mean smoking pack-years was 40.32 ± 35.18. The mean FVC, FEV1, and FEV1/FVC were 3.94 L (75.44%), 2.22 L (58.50%), and 0.53, respectively. The CAT phlegm score at baseline was 3.47 ± 1.06, whereas after 12 weeks of nebulized NAC it significantly decreased to 2.62 ± 1.30 (p < 0.01). More than half (53.5%) of the patients expressed satisfaction with the effects of nebulized NAC therapy. Adverse events occurred in 8 (8.0%) patients. Notably, no serious adverse drug reactions were reported. CONCLUSION: In this study, we have established the effectiveness and safety of nebulized NAC over 12 weeks.


Asunto(s)
Acetilcisteína , Nebulizadores y Vaporizadores , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Acetilcisteína/administración & dosificación , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Masculino , Femenino , Anciano , Estudios Prospectivos , Persona de Mediana Edad , Volumen Espiratorio Forzado/efectos de los fármacos , Administración por Inhalación , Capacidad Vital/efectos de los fármacos , Expectorantes/administración & dosificación , Expectorantes/efectos adversos , Resultado del Tratamiento
2.
World J Gastroenterol ; 30(31): 3635-3639, 2024 Aug 21.
Artículo en Inglés | MEDLINE | ID: mdl-39193004

RESUMEN

Post-embolization syndrome (PES) is the most common complication in patients with hepatocellular carcinoma treated with transarterial chemoembolization. Many strategies have been evaluated to reduce the incidence of PES, but no standard prevention guidelines currently exist. In a single-center, placebo-controlled trial, Simasingha et al evaluated the prophylactic administration of a combination of dexamethasone and N-acetylcysteine and documented a significant reduction in the incidence of PES (from 80% to 6%), of post-procedural liver decompensation (from 14% to 0%), and a shorter hospital stay (4 days vs 6 days), alongside an acceptable safety profile. The results of this study raise several controversial points regarding their applicability in the Western world. In the West, there is a greater and increasing prevalence of metabolic and alcoholic etiologies of liver cirrhosis, so a not negligible number of patients with type II diabetes or hypertension would be excluded from high-dosage dexamethasone prophylaxis. Furthermore, in the West, there is a preferred use of drug-eluting beads loaded with doxorubicin, which are associated with a lower incidence of PES. A study on prophylaxis with dexamethasone and/or N-acetylcysteine in a Western population is hopefully awaited.


Asunto(s)
Acetilcisteína , Carcinoma Hepatocelular , Quimioembolización Terapéutica , Dexametasona , Neoplasias Hepáticas , Humanos , Carcinoma Hepatocelular/terapia , Dexametasona/administración & dosificación , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/epidemiología , Quimioembolización Terapéutica/métodos , Quimioembolización Terapéutica/efectos adversos , Acetilcisteína/administración & dosificación , Acetilcisteína/uso terapéutico , Resultado del Tratamiento , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Quimioterapia Combinada/métodos
3.
NEJM Evid ; 3(9): EVIDoa2300332, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39189858

RESUMEN

BACKGROUND: Tuberculosis remains a global health concern, and half of cured patients have permanent lung injury. N-acetylcysteine (NAC) has shown beneficial antimicrobial, antioxidant, and immunomodulatory effects in preclinical tuberculosis models. We examined its effects on tuberculosis treatment outcomes. METHODS: This prospective, randomized, controlled trial nested within the TB SEQUEL cohort study enrolled 140 adults with moderate or far-advanced tuberculosis. Participants were randomly assigned 1:1 to standard therapy with or without 1200 mg of oral NAC twice daily for days 1 to 112. Clinical evaluations, sputum culture, and spirometry were performed at specified intervals through day 168, after which participants returned to the TB SEQUEL cohort. The primary outcome was culture conversion. Secondary outcomes included whole-blood glutathione levels and lung function. RESULTS: Participants were predominantly young, male, and human immunodeficiency virus 1-negative and had heavy sputum Mycobacterium tuberculosis (MTB) infection burdens. NAC increased glutathione levels (NAC × day interaction, 8.48; 95% confidence interval [CI], 1.93 to 15.02) but did not increase stable culture conversion (hazard ratio, 0.84; 95% CI, 0.59 to 1.20; P=0.33). NAC treatment was associated with improved recovery of lung function (NAC × month, 0.49 [95% CI, 0.02 to 0.95] and 0.42 [95% CI, -0.06 to 0.91] for forced vital capacity and forced expiratory volume in the first second, respectively, as percentages of predicted values). The effects of NAC on lung function were greatest in participants with severe baseline lung impairment and appeared to persist beyond the period of NAC administration. Rates of serious or grade 3 to 4 nonserious adverse events did not differ between the groups. CONCLUSIONS: Despite increasing whole-blood glutathione levels, NAC did not affect eradication of MTB infection in adults with pulmonary tuberculosis that was moderate to far advanced. Secondary outcomes of lung function showed changes that merit further investigation. (Funded by TB SEQUEL grant 01KA1613 of the German Ministry for Education and Research, the Health Africa Project, and the German Center for Infection Research; ClinicalTrials.gov number, NCT03702738.).


Asunto(s)
Acetilcisteína , Antituberculosos , Glutatión , Tuberculosis Pulmonar , Humanos , Acetilcisteína/administración & dosificación , Acetilcisteína/uso terapéutico , Masculino , Tuberculosis Pulmonar/tratamiento farmacológico , Femenino , Adulto , Estudios Prospectivos , Antituberculosos/uso terapéutico , Antituberculosos/administración & dosificación , Glutatión/sangre , Persona de Mediana Edad , Pulmón/efectos de los fármacos , Pulmón/microbiología , Pulmón/fisiopatología , Esputo/microbiología , Resultado del Tratamiento , Pruebas de Función Respiratoria , Adulto Joven
4.
Sci Rep ; 14(1): 18140, 2024 08 05.
Artículo en Inglés | MEDLINE | ID: mdl-39103611

RESUMEN

Rifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC) to improve rifaximin efficacy. In a resazurin checkerboard assay, combining rifaximin with NAC had significant synergistic effects in reducing E. coli levels. The optimal rifaximin + NAC combination was then tested in a validated rat model of IBS-D (induced by cytolethal distending toxin [CdtB] inoculation). Rats were inoculated with vehicle and treated with placebo (Control-PBS) or rifaximin + NAC (Control-Rif + NAC, safety), or inoculated with CdtB and treated with placebo (CdtB-PBS), rifaximin (CdtB-Rifaximin), or rifaximin + NAC (CdtB-Rif + NAC) for 10 days. CdtB-inoculated rats (CdtB-PBS) developed wide variability in stool consistency (P = 0.0014) vs. controls (Control-PBS). Stool variability normalized in rats treated with rifaximin + NAC (CdtB-Rif + NAC) but not rifaximin alone (CdtB-Rifaximin). Small bowel bacterial levels were elevated in CdtB-PBS rats but normalized in CdtB-Rif + NAC but not CdtB-Rifaximin rats. E. coli and Desulfovibrio spp levels (each associated with different IBS-D microtypes) were also elevated in CdtB-inoculated (CdtB-PBS) but normalized in CdtB-Rif + NAC rats. Cytokine levels normalized only in CdtB-Rif + NAC rats, in a manner predicted to be associated with reduced diarrhea driven by reduced E. coli. These findings suggest that combining rifaximin with NAC may improve the percentage of IBS-D patients responding to treatment.


Asunto(s)
Acetilcisteína , Diarrea , Modelos Animales de Enfermedad , Escherichia coli , Síndrome del Colon Irritable , Rifaximina , Animales , Rifaximina/farmacología , Rifaximina/uso terapéutico , Acetilcisteína/farmacología , Acetilcisteína/administración & dosificación , Ratas , Escherichia coli/efectos de los fármacos , Diarrea/tratamiento farmacológico , Diarrea/microbiología , Síndrome del Colon Irritable/tratamiento farmacológico , Síndrome del Colon Irritable/microbiología , Masculino , Ratas Sprague-Dawley , Quimioterapia Combinada
5.
Reprod Domest Anim ; 59(8): e14709, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39189388

RESUMEN

Heat stress (HS) disrupts testicular homeostasis because of oxidative stress. N-acetylcysteine (NAC) is a thiol compound with antioxidants, anti-inflammatory and anti-apoptotic properties. As a sequel, this research aimed to assess the ameliorative effects of NAC supplementation on the reproductive performance of goat bucks kept under environmental HS. Primarily, Doppler examination as well as semen collection and evaluation were conducted on 12 mature bucks for 2 weeks (W) as pre-heat stress control (W1 and W2) during winter (February 2023). The temperature-humidity index (THI) was 63.4-64.3 (winter season). Then during summer HS conditions (from the beginning of July till the end of August 2023) bucks were assessed before NAC supplementation (W0), afterwards they were arbitrarily assigned into two groups. The control group (CON; n = 6) received the basal diet while the NAC group (n = 6) received the basal diet in addition to oral NAC daily for 7 weeks (W1-W7). The THI was 78.1-81.6 (summer season). Testicular blood flow parameters, serum concentration of nitric oxide (NO) and testosterone were measured. Additionally, total antioxidant capacity (TAC) and malondialdehyde (MDA) content in seminal plasma and semen quality parameters were evaluated. There were marked reductions (p < 0.05) in the resistive index (RI; W1, W4 and W5), pulsatility index (PI; W2 and W4-W7), and systolic/diastolic ratio (S/D; W4-W7) in the NAC group compared to the CON group. Furthermore, testosterone and NO levels were higher (p < 0.01 and p < 0.05, respectively) in the NAC group (W2, W3, W5 and W3-W5, respectively). Seminal plasma TAC increased (p < 0.05) and MDA decreased (p < 0.05) in the NAC group (W2, W4 and W5) compared to the CON group. Moreover, there were marked improvements (p < 0.05) in semen quality parameters (mass motility, total motility, viability and normal morphology) in the NAC group. In conclusion, oral NAC supplementation could be used to enhance the reproductive performance of goat bucks during HS conditions which is supported by remarkable enhancement in testicular haemodynamics, NO, testosterone levels and semen quality parameters.


Asunto(s)
Acetilcisteína , Antioxidantes , Suplementos Dietéticos , Cabras , Hemodinámica , Análisis de Semen , Semen , Testículo , Testosterona , Masculino , Animales , Cabras/fisiología , Testículo/efectos de los fármacos , Testosterona/sangre , Acetilcisteína/farmacología , Acetilcisteína/administración & dosificación , Antioxidantes/farmacología , Análisis de Semen/veterinaria , Hemodinámica/efectos de los fármacos , Semen/efectos de los fármacos , Óxido Nítrico/metabolismo , Calor
6.
An Acad Bras Cienc ; 96(3): e20230347, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39046019

RESUMEN

Oxidative stress is involved in the pathogenesis of malaria, causing anemia, respiratory complications, and cerebral malaria. To mitigate oxidative stress, we investigated the effect of nutritional supplementation whit lycopene (LYC) on the evolution of parasitemia and survival rate in mice infected with Plasmodium berghei ANKA (Pb), comparing to the effects promoted by N-acetylcysteine (NAC). Therefore, 175 mice were randomly distributed into 4 groups; Sham: untreated and uninfected animals; Pb: animals infected with Pb; LYC+Pb: animals treated with LYC and infected with Pb; NAC+Pb: animals treated with NAC and infected with Pb. The animals were followed for 12 days after infection, and survival and parasitemia rates were evaluated. There was a 40.1% increase in parasitemia in the animals of the Pb group on the 12th day, and a survival rate of 45%. LYC supplementation slowed the development of parasitemia to 19% and promoted a significative increase in the survival rate of 80% on the 12th day after infection, compared to the Pb group, effects superior to those promoted by NAC, providing strong evidence of the beneficial effect of LYC on in vivo malaria and stressing the importance of antioxidant supplementation in the treatment of this disease.


Asunto(s)
Acetilcisteína , Antioxidantes , Suplementos Dietéticos , Licopeno , Malaria , Parasitemia , Plasmodium berghei , Animales , Licopeno/uso terapéutico , Licopeno/administración & dosificación , Licopeno/farmacología , Parasitemia/tratamiento farmacológico , Ratones , Malaria/tratamiento farmacológico , Acetilcisteína/administración & dosificación , Acetilcisteína/uso terapéutico , Acetilcisteína/farmacología , Plasmodium berghei/efectos de los fármacos , Antioxidantes/uso terapéutico , Antioxidantes/administración & dosificación , Estrés Oxidativo/efectos de los fármacos , Carotenoides/uso terapéutico , Carotenoides/administración & dosificación , Masculino , Modelos Animales de Enfermedad , Distribución Aleatoria
7.
Basic Clin Pharmacol Toxicol ; 135(3): 285-294, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39004668

RESUMEN

N-acetylcysteine (NAC) is regarded as an effective treatment of paracetamol overdoses. However, in cases of "massive" paracetamol overdoses, recent studies indicate that patients may not be sufficiently treated with the standard dose of NAC (300 mg/kg over 20-21 h). The subject is further complicated because "massive overdoses" and "high-risk" are defined differently; some studies use the ingested amount (e.g., >40 g), and some studies use blood concentrations of paracetamol and transaminases. This narrative review investigates whether high-dose NAC significantly decreases the risk of hepatotoxicity in patients with massive paracetamol overdoses. Three observational studies were analysed; one study with 373 patients found no significant difference (odds ratio [OR]: 1.27, 95% confidence interval [CI]: 0.49-3.29). One study with 79 patients found a significant difference (OR: 0.27, 95% CI: 0.08-0.94). The third study with 89 patients found a significant difference in hepatoxicity between the groups (p = 0.043). There are no solid evidence to support that treatment with high-dose NAC significantly reduces the rate of hepatotoxicity in patients presenting with massive paracetamol overdoses. Differences in inclusion criteria in the included studies make the studies incomparable. This paper shows that standardized inclusion is needed to determine whether a high-dose NAC regimen should be included in clinical practice.


Asunto(s)
Acetaminofén , Acetilcisteína , Enfermedad Hepática Inducida por Sustancias y Drogas , Sobredosis de Droga , Acetilcisteína/administración & dosificación , Acetilcisteína/uso terapéutico , Humanos , Acetaminofén/envenenamiento , Acetaminofén/administración & dosificación , Sobredosis de Droga/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Analgésicos no Narcóticos/envenenamiento , Analgésicos no Narcóticos/administración & dosificación , Antídotos/administración & dosificación , Antídotos/uso terapéutico , Relación Dosis-Respuesta a Droga , Estudios Observacionales como Asunto
8.
Clin Toxicol (Phila) ; 62(8): 519-525, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39051728

RESUMEN

BACKGROUND: Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophen) overdose. However, hepatotoxicity is reported despite early treatment when paracetamol concentrations exceed 300 mg/L (1,985 µmol/L) at 4 h. Prior studies evaluating high-dose acetylcysteine to treat high-risk ingestions have shown mixed results. We compared outcomes in patients with high-risk ingestions receiving standard or high-dose acetylcysteine. METHODS: Records from a single poison center were reviewed from 1 January 2017 to 31 December 2022. We included cases of acute paracetamol ingestion treated with intravenous acetylcysteine with an initial paracetamol concentration above the "300 mg/L" (1,985 µmol/L) line on the Rumack-Matthew nomogram. We compared standard and high-dose acetylcysteine groups by odds ratios and multivariable logistic regression. We defined hepatotoxicity as aminotransferase activity >1,000 U/L. RESULTS: We included 190 cases. Fifty-six percent received standard-dose acetylcysteine while 44% received high-dose acetylcysteine. Treatment within 8 h yielded no difference in hepatotoxicity between groups (odds ratio 1.67, 95% CI 0.067-42.3). Among patients treated after 8 h, hepatoxicity was more common in the high-dose group (odds ratio 3.39, 95% CI 1.25-9.2) though odds of liver failure were similar (odds ratio 2.78, 95% CI 0.89-8.69). Eighty-eight percent of patients with hepatotoxicity had elevated aminotransferase activity at presentation. No patient died or received a liver transplant. DISCUSSION: Rates of hepatotoxicity were low in patients treated within 8 h regardless of acetylcysteine dose. Unexpectedly, high-dose acetylcysteine treatment was associated with an increased odds of hepatoxicity in those treated after 8 h, but most had abnormal aminotransferase activities at presentation and there was no difference in rates of liver failure. Limitations include the use of retrospective, voluntarily reported poison center data. CONCLUSIONS: Prompt treatment with acetylcysteine, regardless of dose, prevented hepatotoxicity in high-risk paracetamol ingestion.


Asunto(s)
Acetaminofén , Acetilcisteína , Enfermedad Hepática Inducida por Sustancias y Drogas , Sobredosis de Droga , Humanos , Acetilcisteína/uso terapéutico , Acetilcisteína/administración & dosificación , Acetaminofén/envenenamiento , Acetaminofén/administración & dosificación , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Masculino , Femenino , Sobredosis de Droga/tratamiento farmacológico , Adulto , Estudios Retrospectivos , Persona de Mediana Edad , Antídotos/administración & dosificación , Antídotos/uso terapéutico , Adulto Joven , Analgésicos no Narcóticos/envenenamiento , Analgésicos no Narcóticos/administración & dosificación , Relación Dosis-Respuesta a Droga , Centros de Control de Intoxicaciones/estadística & datos numéricos , Adolescente
9.
J Int Med Res ; 52(7): 3000605241260362, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-39068527

RESUMEN

OBJECTIVE: In 2012, the Commission on Human Medicines mandated lowering the acetaminophen toxicity nomogram treatment threshold in the UK to 100 µg/ml at 4 h post-ingestion. The present study aim was to evaluate biochemical and liver toxicity patterns in patients who presented with acetaminophen overdose and had low serum acetaminophen concentrations (<150 µg/ml). METHODS: Patients admitted to the emergency department with a clear history of acute acetaminophen overdose with or without other medication or ethanol were consecutively enrolled into this retrospective cohort study. Patients with serum acetaminophen concentration >150 µg/ml or an unknown ingestion time were excluded. Data were extracted from electronic medical records and are presented as mean ± SD or median (interquartile range). RESULTS: A total of 103 patients were included (median age, 17 [4-21] years) and 80 (78%) were female. The median ingested acetaminophen dose was 5000 (2850-7650) mg. At baseline, the median serum acetaminophen concentration was 42 (4.5-64.8) µg/ml, and median alanine aminotransferase and aspartate aminotransferase levels were 22 (17-28) and 27 (16-45) IU/L, respectively. Twenty patients were treated with acetylcysteine, with none developing adverse reactions. No patient developed hepatotoxicity, including patients with initial multiple product ingestion or other risk factors. CONCLUSIONS: Patients presenting with an acute acetaminophen overdose with acetaminophen level <150 µg/ml, including patients with other risk factors, are at low risk of hepatotoxicity.


Asunto(s)
Acetaminofén , Enfermedad Hepática Inducida por Sustancias y Drogas , Sobredosis de Droga , Humanos , Acetaminofén/sangre , Femenino , Masculino , Sobredosis de Droga/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Estudios Retrospectivos , Adolescente , Adulto Joven , Niño , Preescolar , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Factores de Riesgo , Acetilcisteína/uso terapéutico , Acetilcisteína/administración & dosificación , Acetilcisteína/sangre , Adulto , Analgésicos no Narcóticos/sangre , Analgésicos no Narcóticos/envenenamiento , Analgésicos no Narcóticos/efectos adversos
10.
Clin Pharmacol Drug Dev ; 13(9): 1051-1060, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38973337

RESUMEN

Myocardial reperfusion injury (MRI) accounts for up to 50% of the final size in acute myocardial infarction and other conditions associated with ischemia-reperfusion. Currently, there is still no therapy to prevent MRI, but it is well known that oxidative stress has a key role in its mechanism. We previously reduced MRI in rats through a combined antioxidant therapy (CAT) of ascorbic acid, N-acetylcysteine, and deferoxamine. This study determines the safety and pharmacokinetics of CAT in a Phase I clinical trial. Healthy subjects (n = 18) were randomized 2:1 to CAT or placebo (NaCl 0.9% i.v.). Two different doses/infusion rates of CATs were tested in a single 90-minute intravenous infusion. Blood samples were collected at specific times for 180 minutes to measure plasma drug concentrations (ascorbic acid, N-acetylcysteine, and deferoxamine) and oxidative stress biomarkers. Adverse events were registered during infusion and followed for 30 days. Both CAT1 and CAT2 significantly increased the CAT drug concentrations compared to placebo (P < .05). Most of the pharmacokinetic parameters were similar between CAT1 and CAT2. In total, 6 adverse events were reported, all nonserious and observed in CAT1. The ferric-reducing ability of plasma (an antioxidant biomarker) increased in both CAT groups compared to placebo (P < .001). The CAT is safe in humans and a potential treatment for patients with acute myocardial infarction undergoing reperfusion therapy.


Asunto(s)
Acetilcisteína , Antioxidantes , Ácido Ascórbico , Deferoxamina , Daño por Reperfusión Miocárdica , Estrés Oxidativo , Humanos , Antioxidantes/farmacocinética , Antioxidantes/administración & dosificación , Antioxidantes/efectos adversos , Antioxidantes/farmacología , Masculino , Acetilcisteína/administración & dosificación , Acetilcisteína/farmacocinética , Acetilcisteína/efectos adversos , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacocinética , Ácido Ascórbico/efectos adversos , Adulto , Estrés Oxidativo/efectos de los fármacos , Femenino , Deferoxamina/farmacocinética , Deferoxamina/administración & dosificación , Deferoxamina/efectos adversos , Voluntarios Sanos , Adulto Joven , Infusiones Intravenosas , Persona de Mediana Edad , Método Doble Ciego , Quimioterapia Combinada , Biomarcadores/sangre
11.
Basic Clin Pharmacol Toxicol ; 135(2): 164-172, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38897728

RESUMEN

Exogenous, well-established antioxidant N-acetylcysteine can reduce or prevent the deleterious effects of pesticides. In this study, utilizing a mouse model of daily single dose of N-acetylcysteine administration, we investigated the impact of this adjuvant on the treatment with atropine and/or obidoxime as well as oxidative stress response in pyrimiphos-methyl-induced toxicity. We found that N-acetylcysteine significantly reduces the oxidative stress generated by pyrimiphos-methyl. The therapy consisting of atropine and/or obidoxime routinely used in organophosphorous insecticide poisonings, including pyrimiphos-methyl, had no effect on the antioxidant properties of N-acetylcysteine. Adjunctive treatment offered by N-acetylcysteine fills therapeutic gap and may provide the full potential against pyrimiphos-methyl-induced toxicity.


Asunto(s)
Acetilcisteína , Antioxidantes , Atropina , Insecticidas , Compuestos Organotiofosforados , Estrés Oxidativo , Animales , Acetilcisteína/uso terapéutico , Acetilcisteína/administración & dosificación , Acetilcisteína/farmacología , Atropina/uso terapéutico , Atropina/administración & dosificación , Atropina/farmacología , Compuestos Organotiofosforados/envenenamiento , Compuestos Organotiofosforados/toxicidad , Ratones , Estrés Oxidativo/efectos de los fármacos , Antioxidantes/farmacología , Antioxidantes/administración & dosificación , Masculino , Insecticidas/toxicidad , Insecticidas/envenenamiento , Síndromes de Neurotoxicidad/etiología , Síndromes de Neurotoxicidad/tratamiento farmacológico , Cloruro de Obidoxima/farmacología , Cloruro de Obidoxima/uso terapéutico , Cloruro de Obidoxima/administración & dosificación , Modelos Animales de Enfermedad , Intoxicación por Organofosfatos/tratamiento farmacológico
13.
Int J Mol Sci ; 25(10)2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38791242

RESUMEN

The objective of this study was to investigate if delivering multiple doses of N-acetylcysteine (NAC) post-surgery in addition to pre-incisional administration significantly impacts the wound healing process in a rat model. Full-thickness skin incisions were carried out on the dorsum of 24 Sprague-Dawley rats in six locations. Fifteen minutes prior to the incision, half of the sites were treated with a control solution, with the wounds on the contralateral side treated with solutions containing 0.015%, 0.03% and 0.045% of NAC. In the case of the NAC treated group, further injections were given every 8 h for three days. On days 3, 7, 14 and 60 post-op, rats were sacrificed to gather material for the histological analysis, which included histomorphometry, collagen fiber organization analysis, immunohistochemistry and Abramov scale scoring. It was determined that scars treated with 0.015% NAC had significantly lower reepithelization than the control at day 60 post-op (p = 0.0018). Scars treated with 0.045% NAC had a significantly lower collagen fiber variance compared to 0.015% NAC at day 14 post-op (p = 0.02 and p = 0.04) and a lower mean scar width than the control at day 60 post-op (p = 0.0354 and p = 0.0224). No significant differences in the recruitment of immune cells and histological parameters were found. The results point to a limited efficacy of multiple NAC injections post-surgery in wound healing.


Asunto(s)
Acetilcisteína , Ratas Sprague-Dawley , Cicatrización de Heridas , Animales , Cicatrización de Heridas/efectos de los fármacos , Acetilcisteína/farmacología , Acetilcisteína/administración & dosificación , Ratas , Inyecciones Intradérmicas , Modelos Animales de Enfermedad , Piel/efectos de los fármacos , Piel/patología , Piel/lesiones , Masculino , Herida Quirúrgica/tratamiento farmacológico , Herida Quirúrgica/patología , Colágeno/metabolismo , Cicatriz/patología , Cicatriz/tratamiento farmacológico
15.
Urologiia ; (1): 129-134, 2024 Mar.
Artículo en Ruso | MEDLINE | ID: mdl-38650418

RESUMEN

An analysis and review of domestic and foreign literature on the role of N-acetylcysteine in the correction of oxidative stress, as well as the problem of oxidative stress, and protection against free radicals are presented in the article. The important role of N-acetylcysteine in replenishing the intracellular glutathione level, which is the main cell antioxidant, has been shown, as well as the potential use of N-acetylcysteine for various pathological conditions and diseases. The relevance of concomitant injury and renal dysfunction, and the experience of the clinical use of N-acetylcysteine as a nephroprotector in patients with concomitant injury in the clinic of the Department of Faculty and Endoscopic Surgery of KBSU named after Kh.M. Berbekov are also described. After reviewing the literature, based on the results of many experimental studies, we can conclude that this pharmacological substance is a very promising for replenishing the intracellular glutathione pool, and it becomes possible to include it in the combined therapy of a number of human diseases.


Asunto(s)
Acetilcisteína , Estrés Oxidativo , Humanos , Acetilcisteína/uso terapéutico , Acetilcisteína/administración & dosificación , Estrés Oxidativo/efectos de los fármacos , Glutatión/metabolismo , Enfermedades Renales/tratamiento farmacológico , Antioxidantes/uso terapéutico
16.
Eur J Pharm Sci ; 197: 106779, 2024 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-38670294

RESUMEN

Orally marketed products nintedanib (NDNB) and pirfenidone (PFD) for pulmonary fibrosis (PF) are administered in high doses and have been shown to have serious toxic and side effects. NDNB can cause the elevation of galectin-3, which activates the NF-κB signaling pathway and causes the inflammatory response. S-allylmercapto-N-acetylcysteine (ASSNAC) can alleviate the inflammation response by inhibiting the TLR-4/NF-κB signaling pathway. Therefore, we designed and prepared inhalable ASSNAC and NDNB co-loaded liposomes for the treatment of pulmonary fibrosis. The yellow, spheroidal co-loaded liposomes with a particle size of 98.32±1.98 nm and zeta potential of -22.5 ± 1.58 mV were produced. The aerodynamic fine particle fraction (FPF) and mass median aerodynamic diameter (MMAD) of NDNB were >50 % (81.14 %±0.22 %) and <5 µm (1.79 µm±0.06 µm) in the nebulized liposome solution, respectively. The results showed that inhalation improved the lung deposition and retention times of both drugs. DSPE-PEG 2000 in the liposome formulation enhanced the mucus permeability and reduced phagocytic efflux mediated by macrophages. ASSNAC reduced the mRNA over-expressions of TLR-4, MyD88 and NF-κB caused by NDNB, which could reduce the NDNB's side effects. The Masson's trichrome staining of lung tissues and the levels of CAT, TGF-ß1, HYP, collagen III and mRNA expressions of Collagen I, Collagen III and α-SMA in lung tissues revealed that NDNB/Lip inhalation was more beneficial to alleviate fibrosis than oral NDNB. Although the dose of NDNB/Lip was 30 times lower than that in the oral group, the inhaled NDNB/Lip group had better or comparable anti-fibrotic effects to those in the oral group. According to the expressions of Collagen I, Collagen III and α-SMA in vivo and in vitro, the combination of ASSNAC and NDNB was more effective than the single drugs for pulmonary fibrosis. Therefore, this study provided a new scheme for the treatment of pulmonary fibrosis.


Asunto(s)
Acetilcisteína , Indoles , Liposomas , Pulmón , Fibrosis Pulmonar , Animales , Indoles/administración & dosificación , Indoles/química , Indoles/farmacocinética , Acetilcisteína/administración & dosificación , Fibrosis Pulmonar/tratamiento farmacológico , Fibrosis Pulmonar/metabolismo , Administración por Inhalación , Pulmón/metabolismo , Pulmón/efectos de los fármacos , Pulmón/patología , Ratones , Masculino , Tamaño de la Partícula
17.
Eur Arch Otorhinolaryngol ; 281(7): 3805-3812, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38649541

RESUMEN

PURPOSE: When operating near cranial motor nerves, transient postoperative weakness of target muscles lasting weeks to months is often observed. As nerves are typically intact at a procedure's completion, paresis is hypothesized to result from a combination of neurapraxia and axonotmesis. As both neurapraxia and axonotmesis involve Schwann cell injury and require remyelination, we developed an in vitro RSC96 Schwann cell model of injury using hydrogen peroxide (H2O2) to induce oxidative stress and investigated the efficacy of candidate therapeutic agents to promote RSC96 viability. As a first step in developing a long-term local administration strategy, the most promising of these agents was incorporated into sustained-release microparticles and investigated for bioactivity using this assay. METHODS: The concentration of H2O2 which reduced viability by 50% was determined to establish a standard for inducing oxidative stress in RSC96 cultures. Fresh cultures were then co-dosed with H2O2 and the potential therapeutics melatonin, N-acetylcysteine, resveratrol, and 4-aminopyridine. Schwann cell viability was evaluated and the most efficacious agent, N-acetylcysteine, was encapsulated into microparticles. Eluted samples of N-acetylcysteine from microparticles was evaluated for retained bioactivity. RESULTS: 100 µM N-acetylcysteine improved the viability of Schwann cells dosed with H2O2. 100 µM Microparticle-eluted N-acetylcysteine also enhanced Schwann cell viability. CONCLUSION: We developed a Schwann cell culture model of iatrogenic nerve injury and used this to identify N-acetylcysteine as an agent to promote recovery. N-acetylcysteine was packaged into microparticles and demonstrated promise as a locally administrable agent to reduce oxidative stress in Schwann cells.


Asunto(s)
Acetilcisteína , Peróxido de Hidrógeno , Estrés Oxidativo , Células de Schwann , Acetilcisteína/farmacología , Acetilcisteína/administración & dosificación , Células de Schwann/efectos de los fármacos , Animales , Estrés Oxidativo/efectos de los fármacos , Ratas , Resveratrol/farmacología , Resveratrol/administración & dosificación , Enfermedades de los Nervios Craneales/etiología , Enfermedades de los Nervios Craneales/tratamiento farmacológico , Melatonina/farmacología , Supervivencia Celular/efectos de los fármacos , Complicaciones Posoperatorias/prevención & control , Antioxidantes/farmacología
19.
J Cardiovasc Pharmacol ; 83(6): 580-587, 2024 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-38467037

RESUMEN

ABSTRACT: Multimers of von Willebrand factor play a critical role in various processes inducing morbidity and mortality in cardiovascular-risk patients. With the ability to reduce von Willebrand factor multimers, N-acetylcysteine (NAC) could reduce mortality in patients undergoing coronary catheterization or cardiac surgery. However, its impact in perioperative period has never been studied so far in regard of its potential cardiovascular benefits. Then, 4 databases were searched for randomized controlled trials that compared in-hospital mortality between an experimental group, with NAC, and a control group without NAC, in patients undergoing coronary catheterization or cardiac surgery. The primary efficacy outcome was in-hospital mortality. Secondary outcomes were the occurrence of thrombotic events, major cardiovascular events, myocardial infarction, and contrast-induced nephropathy. The safety outcome was occurrence of hemorrhagic events. Nineteen studies totaling 3718 patients were included. Pooled analysis demonstrated a reduction of in-hospital mortality associated with NAC: odds ratio, 0.60; 95% confidence interval, 0.39-0.92; P = 0.02. The occurrence of secondary outcomes was not significantly reduced with NAC except for contrast-induced nephropathy. No difference was reported for hemorrhagic events. Subgroup analyses revealed a life-saving effect of NAC in a dose-dependent manner with reduction of in-hospital mortality for the NAC high-dose group, but not for the NAC standard-dose (<3500-mg) group. In conclusion, without being able to conclude on the nature of the mechanism involved, our review suggests a benefit of NAC in cardiovascular-risk patients in perioperative period in terms of mortality and supports prospective confirmatory studies.


Asunto(s)
Acetilcisteína , Cateterismo Cardíaco , Procedimientos Quirúrgicos Cardíacos , Mortalidad Hospitalaria , Humanos , Cateterismo Cardíaco/efectos adversos , Cateterismo Cardíaco/mortalidad , Acetilcisteína/efectos adversos , Acetilcisteína/uso terapéutico , Acetilcisteína/administración & dosificación , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Procedimientos Quirúrgicos Cardíacos/mortalidad , Resultado del Tratamiento , Factores de Riesgo , Medición de Riesgo , Femenino , Ensayos Clínicos Controlados Aleatorios como Asunto , Masculino , Anciano , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA